




Cite this: React. Chem. Eng., 2021, 6,
220
Received 25th November 2020,
Accepted 5th January 2021
DOI: 10.1039/d0re00445f
rsc.li/reaction-engineering
Combining radial and continuous flow synthesis
to optimize and scale-up the production of
medicines†
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Peter H. Seeberger *ab and Kerry Gilmore *ac
Current drug production in batch cannot adapt rapidly to market
demands, evidenced by recent shortages in many markets
globally of essential medicines. Flow chemistry is a valuable tool
for on-demand production of active pharmaceutical ingredients
(APIs). Here, we reveal a new concept to develop and produce
APIs, where an automated synthesizer that works with discrete
volumes of solutions is employed at the discovery stage to
identify the optimal synthetic route and conditions before a
commercially available continuous flow system is used for scale-
up. This concept is illustrated by the synthesis of nifedipine and
paracetamol, in short supply in Germany during the COVID-19
pandemic, and the local anesthetic lidocaine.
Drug production is a space and time-consuming process.
Today, the primary manufacturing, i.e. the production of an
active pharmaceutical ingredient (API), is often outsourced to
a contract manufacturing organization (CMO) and performed
in locations that are geographically separate from the
secondary manufacturing, i.e. the formulation of the final
dosage form.9 This presents problems when needs suddenly
fluctuate due to the lack of rapid flexibility – a challenge
intricately linked to the discontinuous batch mode of
operation that protracts production times to several months.
Batch manufacturing suffers from the need for large
equipment and difficulties in reaction scale-up. Therefore,
pharmaceutical production in a country cannot be adapted
immediately to its needs. Flow chemistry is an attractive
alternative process to overcome the space–time–cost issues
related to the batch production of pharmaceuticals, as
continuous flow processes can be carried out using compact
systems and are readily scalable.2–4,6
On-demand production can help avoid drug shortages
compensating for unexpected fluctuations in API availability.1
Flow processes not only facilitate scale-up, but ensure
reproducibility while transferring the synthesis from the
discovery to the production stage.
Automated synthesizers incorporating continuous flow
techniques have been developed for on-demand API
production,5,10,11 and these modular reconfigurable systems
are now supported by artificial intelligence for retrosynthesis
planning and robotics for the physical reconfiguration of the
system between syntheses.5 An alternative approach relies
not on automated reconfigurability, but on radially arranged,
equally accessible flow reactors in an automated system
capable of sequential, non-simultaneous processes. The
conditions of each step within a radial synthesis are
functionally independent, and reactors can be reused under
different conditions – allowing for facile and rapid
screenings, optimization (of single- or multistep processes),
and synthesis of both linear and convergent pathways.7 The
radial synthesizer is optimal for the discovery stage of the
synthetic process and does not require physical
reconfiguration of the instrument between processes. It is
made from commercially available equipment and the
automation software is freely available.7
Continuous flow protocols can be readily transferred to
radial flow.7 Here, we show that the conditions optimized
during reaction development on the radial synthesizer
(temperature, pressure, concentration, stoichiometry, solvent,
and residence time) are readily translated to a commercial
continuous flow system for scale-up. To illustrate the
importance of rapid access to convenient routes to APIs and
their rapid scale-up, we selected paracetamol (1) and
nifedipine (2), two APIs that were in short supply in several
European countries8 during the COVID-19 pandemic, as well
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as the synthesis of lidocaine (3) that was in shortage in
Sweden8 and is often in short supply in Canada12 (Fig. 1a).
Radial synthesizer
The radial synthesizer7 (Fig. 1b) is composed by four main
sections: the reagent delivery system (RDS) where reagents
are mixed and added to the reaction, the central switching
station (CSS) that connects to all reactors; the standby
module (SM) for intermediate storage, and the collection
vessels (C). These four sections are accessible by the flowing
solution via six main pathways, defined by the starting point
and destination of the reagent stream (Fig. 1c). Each pathway
proceeds through the CSS and the chosen reactor at the
conditions set.
For single step syntheses such as paracetamol (1) and
nifedipine (2) (Fig. 1d and e, respectively), the solution flows
from the RDS, through the CSS, and is sent to a collection
vessel (C) for purification or analysis (termed the R–C path).
For multistep syntheses, such as for lidocaine (3) (Fig. 1f),
the solution coming from the RDS in the first step will
proceed to the SM (R–S path) for intermediate storage. In the
second step, this intermediate solution (stored in the SM) is
mixed with additional reagents coming from the RDS and
collected (S–C path).
The chemical transformations of the three syntheses
described here are performed either at room or elevated
temperature. All of these transformations are performed
using the same PFA 10 mL coil reactor, as temperature and
flow rate can be set independently for each synthetic step.
The latter allows for different residence times can be
achieved within the same 10 mL reactor. Long residence
times can be achieved using the stop-flow mode, a function
of the radial synthesizer that seals the reaction mixture
inside a specific module by diverting the carrier gas stream
through different ports of the CSS.
Synthesis of paracetamol (1)
Paracetamol, a commonly used and inexpensive painkiller,
was in short supply in Germany during the COVID-19
pandemic in early 2020.8 Aiming at developing a scalable
process for the production of paracetamol from starting
materials available in Europe, we evaluated the possible
starting points for the synthesis. Phenol,14 4-nitrophenol,15
and 4-aminophenol16 can serve as starting materials.
Fig. 1 a) The painkiller paracetamol (1), the hypertension drug nifedipine (2) and the local anesthetic lidocaine (3) are on the WHO list of essential
drugs.13 b) Main sections of the radial synthesizer: reagent delivery system (RDS), central switching station (CSS), standby module (SM) and
collection vessels (C). c) Six pathways of solution flow through the instrument are described by the starting location of the reagents and their
destination. For example, R–C refers to a solution starting in the RDS and ending in the collection vessel. d) Reagents and pathway for the radial
synthesis of paracetamol (1). e) Reagents and pathway for the radial synthesis of nifedipine (2). f) Reagents and pathways for the radial synthesis of
lidocaine (3).
Fig. 2 Two potential routes for the synthesis of paracetemol, starting
from either (a) phenol, 4-nitrophenol, or 4-aminophenol, or (b)
hydroquinone. Prices for all potential starting materials from Merck's
web catalogue on 08/07/2020.
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4-Aminophenol is the most cost-efficient starting material
(Fig. 2a). An alternative route starts from hydroquinone and
uses ammonium acetate for para-aminophenol formation
and acetylation17 (Fig. 2b), but this is more expensive than
the simple acetylation of 4-aminophenol.
Optimization of the synthesis of 1 in the radial synthesizer
A solution of 4-aminophenol (4) in a mixture of water/acetic
acid (4 : 1, 2 M) and neat acetic anhydride (5) were placed in
the reagent delivery system (RDS) of the radial synthesizer.
Screening of temperature and residence time were performed
selecting the R–C pathway, using 0.5 mL of each reagent
solution per experiment (Fig. 1d, see ESI† for details).
The reaction proceeded smoothly in five minutes at room
temperature with no precipitation observed when using neat
acetic anhydride (5). Rapid screening of the reaction
stoichiometry revealed that direct product crystallization
begins sooner when fewer equivalents of acetic anhydride are
employed. Paracetamol crystallizes ten minutes after addition
when working with three equivalents of 5.
Scale up of the synthesis of 1 in continuous flow
This process was scaled up feeding a solution of 4 in water/
acetic acid (4 : 1; 2 M) from pump A and neat acetic
anhydride (5) from pump B. When a 10 mL coil reactor was
used, the two feeds were set at 1.5 and 0.45 mL min−1
respectively to achieve the optimized five minute residence
time, and the resulting solution was collected upon reaction
in a flask and stirred at room temperature for 1 h. Running
the system for 15 minutes we achieved 6.36 g of crystallized 1
(94% yield) (Fig. 3a). Productivity for this process was 25.6 g
h−1, translating to 1229 doses per day (see electronic
supplementary information for productivity calculations).
The occurrence of spontaneous crystallization after
reaction completion presents the opportunity for a telescoped
in-line crystallization module (Fig. 3b). This module was
based on the SMBR (serial micro-batch reactors) technique18
that generates a segmented flow, spaced by nitrogen gas, to
efficiently transport heterogeneous material in flow.
Crystallization occurs in droplets and the slurry exiting the
telescoped process is directly filtered, providing pure crystals
of paracetamol. To achieve a sufficient residence time (30
min) in the crystallization module (20 mL, i.d. 1.6 mm PFA
coil around a 1 L glass bottle at 25 °C), the size of the reactor
coil was decreased from 10 mL to 1.5 mL and the flow rates
to 0.25 mL min−1 and 0.075 mL min−1, respectively, for
pumps A and B. The N2 flow rate was set at 0.5 mL min
−1.
Collecting for 15 minutes on the filter resulted in 634 mg of
paracetamol (56%). Longer crystallization times (1 h) were
achieved by doubling the length of the crystallization
module. While this resulted in a significant increase in
crystallization yield (93%), process instability due to
aggregation issues within the droplets was also observed.
Lower temperatures for the crystallization module did not
have an impact on yield.
Synthesis of nifedipine (2)
Nifedipine is used to treat angina and hypertension19 and
was in short supply in Germany during the COVID-19
pandemic. Nifedipine is synthesized in batch through a one-
step multicomponent reaction mixing 2-nitrobenzaldehyde 6,
methyl acetoacetate 7, and methyl 3-aminocrotonate 8 at
elevated temperatures in alcohol solvents for several
hours.20–22
Optimization of the synthesis of 2 in the radial
synthesizer. Ethanol and methanol were compared as
solvents for the synthesis of 3. The transesterification by-
products observed during the reaction in ethanol at high
temperature were avoided when methanol was used as a
solvent. A solution of 6 in methanol (0.5 M) and a solution
containing 7 (1.1 equiv.) and 8 (1 equiv.) in methanol were
loaded in the reagent delivery system to screen different
conditions using the R–C path in the radial synthesizer
(Fig. 1e).
In an effort to accelerate the reaction, temperatures from
90 °C to 150 °C, and residence times between 5 and 90 min
were investigated. The reaction time decreased with
increasing temperature and the best yield was achieved at a
60 min residence time – using stop-flow mode – at 150 °C.
Scale up of the synthesis of 2 in continuous flow. For the
scale up of this process, solutions of 6 (1 equiv., 0.5 M), 7
(1.1 equiv.) and 8 (1 equiv.) in methanol were fed to a heated
Fig. 3 Continuous flow synthesis of paracetamol (1) using a
Vapourtec R2 pump module and a room temperature PFA reactor coil
(10 mL, i.d. 0.8 mm). a) The product crystallized when the solution
exiting the flow setup was stirred for 1 h. b) The product was
crystallized inline using an SMBR system, with nitrogen introduced via
a T-mixer and a 20 mL reactor (i.d. 1.6 mm) wrapped around a 1 L flask
at room temperature. Crystals were collected on filter paper.
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10 mL stainless steel coil reactor (150 °C) at 0.167 mL min−1.
The starting material was fully consumed and the crude NMR
showed the clean formation of the desired product within 60
min (Fig. 4). The crude product was collected for 150 min (25
mL) and purified by crystallization offline, yielding 3.06 g of
crystallized nifedipine (2) (71% yield). Productivity for this
process was 1.2 g h−1 that translates to 2880 doses per day
(see ESI† for productivity calculations).
Synthesis of lidocaine (3)
The widely employed local anaesthetic23 lidocaine is
produced via a two-step process. In the first step,
2,6-dimethyl aniline 9 reacts with chloroacetyl chloride 10 to
give 2-chloro-N-(2,6-dimethylphenyl)acetamide 11. In the
second step, diethylamine 12 substitutes the chlorine atom
yielding the final product. Several flow syntheses of lidocaine
have been reported,5,10,24,25 including on automated
synthesizers.5,10,24
Optimization of the synthesis of 3 in the radial
synthesizer. The reagent delivery system was loaded with a
solution of 2,6-dimethyl aniline 9 (1 M in N-methyl-2-
pyrrolidone (NMP)) and a solution of chloroacetyl chloride 10
(1.15 M in NMP) to screen the conditions for the first step
using the R–C path. The reaction is completed in ten minutes
at room temperature, though previously reported to require
120 °C.5,10
A second step was coupled using the overall R–S + S–C
pathway. Two new solutions were loaded in the RDS: a
solution of KOH (0.6 M in methanol/water 1 : 1) and a
solution of diethylamine 12 (1.5 M in methanol/water 1 : 1)
and were mixed with the reaction mixture of the first step
containing intermediate 11 delivered from the standby
module (Fig. 1f). The crude reaction mixture exited the
synthesizer and was extracted offline with hexane and NH4Cl/
NaCl (1 : 1) and crystallized as the hydrochloride salt (see
ESI†). The highest overall yield (62%) is achieved when the
second step is performed with a residence time of 20 minutes
at 130 °C, in agreement with previous literature reports.5,10
Scale-up of the synthesis of 3 in continuous flow. The
synthesis of 3 was scaled up in a 1.6 mL PFA coil at room
temperature for the first step. Solutions of 9 (1 M in NMP)
and 10 (1.15 M in NMP) were pumped at 0.08 mL min−1 each
to achieve the ten minute residence time. The second step
was telescoped pumping a solution of diethylamine 12 (0.75
M) and KOH (0.3 M) in methanol/water 1 : 1 at 0.34 mL min−1
(total flow rate 0.5 mL min−1) through a 10 mL stainless steel
coil heated at 130 °C (residence time = 20 min) (Fig. 5). The
crude reaction mixture was collected for 90 minutes (45 mL)
and was extracted offline with hexane and NH4Cl/NaCl (1 : 1)
to obtain 1.15 g of lidocaine hydrochloride after
crystallization (59% yield). Productivity for this process was
0.8 g h−1 that translates to 19.2 g per day (see ESI† for
productivity calculations).
Conclusions
In summary, the flexibility and responsiveness of
pharmaceutical production needs to be significantly
increased. In light of the recent global disruptions to the
current distributed supply chains, as well as the heavy
reliance on CMOs, an alternative approach is needed. Using
a highly flexible automated flow chemistry platform such as a
radial synthesizer, reproducible API syntheses can rapidly be
adapted or developed. Herein we have shown the conditions
developed and optimized on the radial synthesizer are readily
transferred to a dedicated continuous flow system for scale
up. Processes were developed for three WHO essential
medicines that have been in short supply during the COVID-
19 pandemic: paracetamol, lidocaine, and (for the first time
in flow) nifedipine.
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Fig. 4 Continuous flow synthesis of nifedipine 2 in a Vapourtec R2
pump module using one feed (A) and a stainless-steel reactor coil (10
mL, i.d. 0.8 mm) heated by a Vapourtec R4 module.
Fig. 5 Continuous flow synthesis of lidocaine 3. First step: two feeds
(A and B), are mixed in a T-junction and reacted at room temperature
in a 1.6 mL PFA coil (i.d. 0.8 mm). Second step: the solution exiting the
first reactor is combined with a third feed (C) and passes through a
stainless-steel reactor (i.d. 0.8 mm) at 130 °C.
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